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Background. Persistent asthma is characterized by airway remodeling. Whereas we have previously shown that neither β2-agonists
nor corticosteroids inhibit extracellular matrix (ECM) protein release from airway smooth muscle (ASM) cells, the eﬀect of their
combination is unknown and this forms the rationale for the present study. Methods. ASM cells from people with and without
asthma were stimulated with TGFβ1(1ng/ml) with or without budesonide (10−8 M) and formoterol (10−10 and 10−8 M), and
ﬁbronectin expression and IL-6 release were measured by ELISA. Bronchial rings from nonasthmatic individuals were incubated
with TGFβ1(1ng/ml) with or without the drugs, and ﬁbronectin expression was measured using immunohistochemistry. Results.
Budesonide stimulated ﬁbronectin deposition, in the presence or absence of TGFβ1, and this was partially reversed by formoterol
(10−8 M) in both asthmatic and nonasthmatic cells. Budesonide and formoterol in combination failed to inhibit TGFβ-induced
ﬁbronectin in either cell type. A similar pattern of expression of ﬁbronectin was seen in bronchial rings. TGFβ1-induced IL-6
release was inhibited by the combination of drugs. Conclusion. Current combination asthma therapies are unable to prevent or
reverse remodeling events regulated by ASM cells.
1.Introduction
Airway remodeling, including alterations in the thickness of
the basement membrane, an increase in the number of mu-
cus producing cells, an increase in the number of blood ves-
sels (angiogenesis), and a change in the extracellular matrix
(ECM) protein proﬁle and hypertrophy/hyperplasia result-
ing in an increase in the bulk of the airway smooth muscle
(ASM), is now recognized as a hallmark feature of asthma.
Little is known about the eﬀectiveness of current asthma
therapies upon these structural changes in the airways, par-
ticularly in the vicinity of the ASM.
We have previously reported that neither corticosteroids
nor long-acting β2-agonists (LABAs) alone are eﬀective at
preventing or reversing in vitro parameters of ASM-driven
airway remodeling [1]. The critical question that remained
waswhetherthecombinationofthesetwodrugclasseswould
be more eﬀective.
Whilst the combination of inhaled corticosteroids and
LABAs improves asthma control and lung function and
decreases the frequency of asthma exacerbations compared
to placebo or high doses of inhaled corticosteroids alone
[2–6], few studies have examined their eﬀectiveness at al-
tering parameters of remodeling in vivo. One exception is
the study by Orsida and colleagues who reported that the
combination of LABAs and inhaled corticosteroids reduces
blood vessel number [7]. Given our previous ﬁnding of the
lack of eﬀectiveness of these drugs singly in reducing param-
eters of airway remodeling, it was vital to assess their eﬃcacy
in combination.
Several studies have examined the in vitro eﬀectiveness
of combined corticosteroids and LABAs in ﬁbroblasts with
conﬂicting results. Goulet et al. found that corticosteroids
and LABAs had opposing eﬀects on matrix protein depo-
sition in the presence of serum and their combination
counteracted each other [8]. In contrast, also in ﬁbroblasts,
Descalzi et al. reported corticosteroids had signiﬁcant anti-
proliferative eﬀects and that combination with LABAs
strengthened these eﬀects [9]. Todorova et al. reported that
corticosteroids reduced and the combination with LABAs2 Journal of Allergy
Table 1: Patient details.
Patient no. Age (yrs) Sex Disease Source of tissue Sample type
1 76 Female Chronic obstructive pulmonary disease Endobronchial biopsy ASM
2 43 Female Asthma Endobronchial biopsy ASM
3 26 Male Asthma Endobronchial biopsy ASM
4 66 Male Chronic obstructive pulmonary disease Resection ASM
5 22 Male Asthma Endobronchial biopsy ASM
6 38 Female Carcinoid (atypical) Resection ASM
7 46 Female Carcinoma Resection ASM
8 58 Male Emphysema Explanted lungs ASM
9 50 Female Asthma Endobronchial biopsy ASM
10 56 Female Emphysema Explanted lungs ASM
11 40 Male Asthma Endobronchial biopsy ASM
12 27 Male Asthma Endobronchial biopsy ASM
13 68 Female Carcinoma Resection ASM
14 55 Male Emphysema Explanted lungs ASM
15 64 Female Emphysema Explanted lungs ASM
16 21 Male Asthma Endobronchial biopsy ASM
17 25 Female Bronchiolitis Obliterans Explanted lungs Bronchial rings
18 48 Female Emphysema Explanted lungs Bronchial rings
ASM: airway smooth muscle.
abolished proteoglycan production induced by serum [10].
In the absence of serum, regardless of whether transforming
growth factor β (TGFβ) was present or not, ﬂuticasone in-
creased ﬁbronectin at both the mRNA and protein levels;
however, it decreased tenascin-C at both levels. Salmeterol
did not aﬀect ﬁbronectin or tenascin-C nor did it alter the
eﬀect of ﬂuticasone when the drugs were applied in combi-
nation [11].
Whilst we, and others, have begun elucidating the mo-
lecular mechanism underlying the synergistic eﬀect of the
combination of corticosteroids and LABAs in ASM cells
[12, 13], the eﬀect of the combined drugs on the release of
ECM proteins from ASM cells remains to be investigated.
In this study, we hypothesized that the combination of
corticosteroids and LABAs would be ineﬀective at inhibiting
the production of ECM proteins in vitro. To investigate this
hypothesis, we examined the eﬀect of the combination of
corticosteroids and LABAs in a well-characterized model
of in vitro airway remodeling [1], namely, TGFβ-induced
ﬁbronectininhumanasthmaticandnonasthmaticASMcells
in vitro and in nonasthmatic bronchial rings ex vivo.
2.MaterialsandMethods
2.1. Cell Culture. Approval for all experiments with human
lung was provided by the Human Ethics Committees of
The University of Sydney and the Sydney South West Area
HealthService.AsthmaticASMwasobtainedfrom7patients
(mean age 32.7 ± 11.5 years SD) either undergoing resection
for lung transplantation or deep endobronchial biopsies.
Nonasthmatic ASM was obtained from bronchial airways
of 9 patients (mean age 58.6 ± 11.6 years SD) undergoing
resection for either lung transplantation or carcinoma. The
characteristics of the patients are listed in Table 1.P u r e
ASM bundles were dissected free and grown as explants as
previously described [13–15]. ASM cell characteristics were
determined by light microscopy and immunoﬂuorescence
for the detection of α-smooth muscle actin and calponin
[16]. All experiments were performed with cells between
passages 4 and 8.
2.2. Airway Smooth Muscle Cell Treatment. ASM cells from
6 asthmatic and 8 nonasthmatic patients were seeded for
24 hours in 5% fetal bovine serum (FBS) (JRH Biosciences,
Melbourne, Australia) Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) (SAFC Biosciences, Lenexa, KS) in the presence of
20U/mL penicillin, 20μg/mL streptomycin, and 2.5μg/mL
amphotericin B (Invitrogen, Heidelberg, Australia) at a
density of 1 × 104 cells per cm2. Medium was then changed
to 0.1% insulin transferrin selenium (ITS) (Invitrogen,
Heidelberg, Australia) DMEM for 24 hours before addition
of formoterol (0.1 and 10nmol/L) and budesonide (0.1
and 10nmol/L) alone or in combination as indicated 30
minutes prior to stimulation with TGFβ1 (1ng/mL) for the
time periods described below. The eﬀect of the drugs in
unstimulated cells was assessed by omission of the TGFβ
stimulation in cells maintained in 0.1% ITS. All of the drugs
were dissolved in aqueous solutions.
2.3. ELISAs
2.3.1. Deposited ECM Protein ELISAs. ASM cells from 6
asthmatic and 6 nonasthmatic patients were seeded in 96
well plates and treated as described above for 48 hours. ECM
f r e eo fc e l l sw a sp r e p a r e db yt r e a t m e n twi t hs t e r i l eh yp o t o n i c
ammonium hydroxide [17–19]. Fibronectin was measured
by ELISA as previously described [19] using an antibody to
ﬁbronectin (mouse antihuman plasma ﬁbronectin 2μg/mL,Journal of Allergy 3
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Figure 1: Eﬀect of combined corticosteroids and LABAs on the deposition of ﬁbronectin in the absence (a) or presence of TGFβ (b) for
48hrs, respectively. Data are mean ± SEM from n = 6 asthmatic (black bars) and nonasthmatic (white bars) ASM cell lines. ∗Signiﬁcantly
diﬀerent from nondrug-treated control P<0.05. F: formoterol, B: budesonide.
clone 868A11, Chemicon, Temecula CA) and a puriﬁed
mouse IgG1 isotype control 2μg/mL, clone MOPC-31C,
(Becton and Dickinson Pharmingen, San Jose, CA).
2.3.2. IL-6 ELISAs. ASM cells from 6 asthmatic and 8 non-
asthmatic patients were seeded in 24 well plates and treated
as described above for 48 hours. Supernatants were collected
in aliquots and stored at −20◦C until analysis. IL-6 release
was detected using an IL-6 ELISA kit according to the man-
ufacturer’s instructions (Duoset, Becton and Dickinson, San
Jose, CA).
2.3.3. Soluble Fibronectin ELISAs. Supernatants collected as
described above were also assayed for soluble ﬁbronectin
release using a Quantimatrix Human ﬁbronectin ELISA kit
according to the manufacturer’s instructions (Chemicon In-
ternational, Temecula, CA).
2.3.4. Immunohistochemistry. Human lung tissue was ob-
tained from lung specimens resected for carcinoma or trans-
plantation. Bronchial rings (2–5mm diameter and 3mm in
length) were dissected free from surrounding parenchymal
tissue. The bronchial rings were incubated in treatments
as described above. After 24 hours, tissues were frozen in
optimal cutting temperature (OCT) embedding medium
(Fronine Laboratory Supplies, Riverstone, Australia), sec-
tioned on a cryostat and immunohistochemistry performed
using mouse anti-ﬁbronectin (1μg/mL Chemicon Interna-
tional, Temecula, CA) coupled with a horseradish peroxidase
labeled polymer. To help identify the morphology of the
tissue,hematoxylinandeosin(H&E)stainingwasperformed
on adjacent sections. Full details of this method have been
described previously [1].
2.3.5. Analysis of Data. For ECM ELISA data, results from
duplicate wells from each individual subject were averaged
and the absorbance from media alone subtracted before an
overall mean and standard error of the mean (SEM) were
obtained from asthmatic and nonasthmatic cells. Analysis of
variance (ANOVA) repeated measures with bonferonni post-
tests or student’s paired t-tests were performed on the results
for ECM ELISAs where appropriate. In all cases a P value of
less than or equal to 0.05 was considered signiﬁcant.
3. Results
3.1. Eﬀect of Combined Corticosteroids and LABAs on Basal
ECM Protein Deposition. Budesonide alone (10−8M) induc–
ed ﬁbronectin deposition in both asthmatic and non-
asthmatic ASM cells (Figure 1), in agreement with our pre-
vious study [1]. The addition of formoterol (10−8Mb u t
not 10−10M) abolished the induction of ﬁbronectin by
budesonide 10−10Ma n d1 0 −8M( Figure 1(a) and Table 2).
3.2. Eﬀect of Combined Corticosteroids and LABAs on TGFβ
Stimulated ECM Protein Deposition. TGFβ induced the de-
position of ﬁbronectin from both asthmatic and nonasth-
matic ASM cells, in agreement with our previous reports
[1, 20, 21]( Figure 1). The addition of formoterol (10−10M
and 10−8M) or budesonide (10−8Mo r1 0 −10M), alone or
in combination, did not signiﬁcantly alter ﬁbronectin de-
position in the presence of TGFβ in either cell type.
3.3. Eﬀect of Combined Corticosteroids and LABAs on TGFβ
Stimulated Soluble Fibronectin Release. The release of soluble
ﬁbronectin from asthmatic and nonasthmatic ASM cells was
increased by TGFβ but the presence of the drugs, in any
combination,didnotalterthereleaseofﬁbronectin(datanot
shown).
3.4.EﬀectofCombinedCorticosteroidsandLABAsonBasalIL-
6R e l e a s e . In nonasthmatic ASM cells, budesonide (10−8M)
alone signiﬁcantly reduced the release of IL-6. The addi-
tion of formoterol (10−10 or 10−8M) did not reverse this
reduction (Figure 2(a) and Table 3). The release of IL-6 from
asthmaticASMcellswasmorevariablebutfollowedthesame
pattern.4 Journal of Allergy
Table 2: Eﬀect of combined corticosteroids and LABAs on basal and TGFβ-stimulated ECM protein deposition.
Asthmatic Alone Nonasthmatic Alone
—F 1 0 −10MF 1 0 −8M— F 1 0 −10MF 1 0 −8M
Alone
— 104.8 ±6.7— 9 2 .3 ±2.5
B1 0 −10M 111.5 ±9.2B 1 0 −10M 108.5 ±2.1
B1 0 −8M 166.4 ±13.4∗ 154.8 ±13.0 137.1 ±8.3B 1 0 −8M 140.5 ±7.4∗ 137.3 ±7.7 117.9 ±4.4
TGFβ stimulated TGFβ stimulated
—F 1 0 −10MF 1 0 −8M— F 1 0 −10MF 1 0 −8M
TGFβ stimulated
—7 8 .3 ±2.5∗ —8 7 .4 ±2.0∗
B1 0 −10M9 3 .6 ±3.8B 1 0 −10M9 8 .5 ±3.6
B1 0 −8M 113.5 ±10.2 116.0 ±8.19 7 .1 ±6.5B 1 0 −8M 114.1 ±3.0∗ 114.2 ±2.8 102.3 ±2.7
F: formoterol, B: budesonide.
D a t aa r ee x p r e s s e da s%0 . 1 %I T Sf o rd r u g sa l o n ea n d%T G F β for TGFβ-stimulated samples.
∗signiﬁcantly diﬀ to 0.1% ITS or TGFβP<0.05. n = 6 asthmatic and 6 nonasthmatic.
Table 3: Eﬀect of combined corticosteroids and LABAs on basal and TGFβ-stimulated IL6 release.
Asthmatic Alone Nonasthmatic Alone
—F 1 0 −10MF 1 0 −8M— F 1 0 −10MF 1 0 −8M
Alone
— 275.6 ±71.4 — 224.0 ±68.2
B1 0 −10M 208.3 ±54.8B 1 0 −10M 181.5 ±51.6
B1 0 −8M3 1 .9 ±12.75 4 .1 ±22.5 166.6 ±48.7B 1 0 −8M2 3 .35 ±2.57 8 .13 ±47.5 187.1 ±112.7
TGFβ stimulated TGFβ stimulated
—F 1 0 −10MF 1 0 −8M— F 1 0 −10MF 1 0 −8M
TGFβ stimulated
—6 8 .2 ±9.2— 7 4 .1 ±9.5
B1 0 −10M5 5 .8 ±7.9B 1 0 −10M5 8 .78 ± 5.4
B1 0 −8M1 3 .7 ±3.61 3 .7 ±4.02 1 .1 ±5.5B 1 0 −8M2 0 .0 ±1.91 7 .3 ±2.91 7 .6 ±2.9
F: formoterol, B: budesonide.
Data are expressed as mean ±SEM % 0.1% ITS for drugs alone and % TGFβ for TGFβ-stimulated samples. n = 6 asthmatic and 8 nonasthmatic.
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Figure 2: Eﬀect of combined corticosteroids and LABAs on the release of IL-6 in the absence (a) or presence of TGFβ (b) for 48hrs
respectively. Data are mean ± SEM from n = 6 asthmatic (grey boxes) and n = 8 nonasthmatic (white boxes) ASM cell lines. Signiﬁcantly
diﬀerent from nondrug-treated control ∗P<0.05, #P<0.005, $P<0.001. F: formoterol, B: budesonide.Journal of Allergy 5
Fibronectin
Isotype
control
0.1%ITS 0.1%ITS
TGFβ 1 ng/mL
F1 0 −8M
F1 0 −8M
B1 0 −10M
B1 0−8M
B1 0 −8M
F 10−10M F1 0 −8M
B1 0 −8M
Figure 3:EﬀectofcombinedcorticosteroidsandLABAonTGFβ-inducedﬁbronectininnonasthmaticbronchialrings.Immunohistochemi-
caldetectionofﬁbronectin(brownstaining)basallyorfollowing stimulationwithTGFβ inthepresenceorabsence ofdrugsinnonasthmatic
tissue sections.
3.5. Eﬀect of Combined Corticosteroids and LABAs on TGFβ
Stimulated IL-6 Release. In both cell types, TGFβ signiﬁ-
cantly induced the release of IL-6. Budesonide reduced the
releaseofIL-6eveninthepresenceofTGFβ inbothcelltypes
(Figure 2(b)andTable 3).Onceagain,formoterol(10−10 and
10−8M) did not reverse the inhibitory eﬀect of budesonide
(asthmatic 13.66 ± 4.0 and 21.08 ± 5.5, nonasthmatic 17.34
± 2.9 and 17.55 ± 2.9% of TGFβ)( Figure 2(b)).
3.6. Eﬀect of Combined Corticosteroids and LABAs on
Fibronectin Expression in Bronchial Tissue Rings. To examine
the eﬀectiveness of the combination of corticosteroids and
LABAs on ECM deposition in the whole airway, we used
our ex vivo bronchial ring model [1, 20]. Bronchial rings
from two nonasthmatic individuals stimulated with TGFβ
showed increased deposition of ﬁbronectin, in agreement
with our previous ﬁndings [1, 20]. Neither formoterol nor
budesonide alone, or in combination, reduced the TGFβ-
induced ﬁbronectin deposition (Figure 3).
4. Discussion
Our previous work demonstrated that neither long-acting
beta agonists nor corticosteroids reduced the release of ECM
proteinsfromASMcells.Thequestionremainedastowheth-
er the combination of these two therapeutic drug classes
m i g h tb em o r ee ﬀective. The results of the current study
with formoterol and budesonide demonstrate that this is not
the case, regardless of whether the cells were derived from
asthmatic or nonasthmatic subjects. Moreover, in bronchial
rings stimulated with TGFβ, ﬁbronectin deposition was not
reduced by formoterol, budesonide, nor their combination.
There are many examples of the eﬃcacy of combined
LABAs and corticosteroids in both in vivo [5, 22]a n din vitro
[13, 23–25] studies. There are very few reports, however, of
the modulation of remodeling parameters by these drugs,
although the combination of LABAs and inhaled corticos-
teroids does reduce angiogenesis—one of the features of
remodeling [7]. In addition, we have reported a synergistic
inhibitionofASMproliferationwhenthesedrugsarestudied
in combination [13]. However, budesonide and salbutamol,
alone or in combination, had no eﬀect on collagen ﬁber trac-
tional remodeling as ASM cells migrated through collagen
gels [26]. Descalzi et al. [9] found that the combination of
beclomethasone dipropionate (BDP) with either a short or
long-acting beta agonist decreased ﬁbronectin production
induced by basic ﬁbroblast growth factor, and that this eﬀect
was greater than with BDP alone. Their study was carried
out in ﬁbroblasts stimulated with basic ﬁbroblast growth
factor, as opposed to smooth muscle cells stimulated with
TGFβ in the current study, and this may be the basis for
thediﬀerencesobserved.Again,inﬁbroblasts,corticosteroids
in the presence of serum increased ECM deposition, which
we also found in ASM cells, but LABAs decreased ECM
deposition and the net result of the combination was simply
additive [8]. In contrast, Degen et al. found, in ﬁbroblasts,
thatﬂuticasoneincreasedﬁbronectinbutdecreasedtenascin-
C mRNA and protein induced by FBS, TGFβ, or in the
absence of stimulation. Under these experimental conditions
salmeterol did not inﬂuence the ﬂuticasone eﬀects [11].
We also examined the eﬀect of corticosteroids and LABAs
alone and in combination on TGFβ-induced soluble, as
opposed to matrix-associated, ﬁbronectin release but again
these interventions were without eﬀect in either asthmatic or
nonasthmatic cells. To our knowledge, there are no previous
reports examining the eﬀect of combination therapy in
asthmatic ASM.
A consistent ﬁnding from our laboratory has been the
increase in release of ECM proteins from ASM in response
to corticosteroids. Beclomethasone increased release of ﬁ-
bronectin from ASM [19] and this eﬀect has also been re-
ported by Goulet et al. and Degen et al. in human airway
ﬁbroblasts using several corticosteroids [8, 11]. This is con-
sistent with the fact that budesonide increased ﬁbronectin
release from ASM cells derived from both asthmatic and
nonasthmatic subjects in our current study, and further-
more this occurred whether or not cells were stimulated
with TGFβ. Interestingly, formoterol was able to attenu-
ate budesonide-induced ECM ﬁbronectin deposition even
though alone it was without eﬀect. The diﬀerential response
of ﬁbroblasts to ﬂuticasone in relation to the production of
ﬁbronectin and tenascin-C observed by Degen et al. [11]
suggests that the individual ECM proteins may respond6 Journal of Allergy
diﬀerently to therapeutic intervention. Therefore, caution
should be taken in interpreting the results of this in vitro
studyasaglobalrepresentationoftheeﬀectivenessofcurrent
therapies on altering parameters of airway remodeling.
Although we found in the present study that the combi-
nation of LABAs and corticosteroids did not decrease
ﬁbronectin release, corticosteroids, as previously reported
[1,27],inhibitedIL-6releasefromtheASMcells.Baouzetal.
reported that in (myo) ﬁbroblasts, salmeterol inhibited IL-6
release, and this was ampliﬁed by the addition of low con-
centrations of ﬂuticasone dipropionate [28]. Others have
found, also in ﬁbroblasts, that corticosteroids inhibited and
LABAs had no eﬀect on IL-6 release and the eﬀect of
the combination was that of corticosteroids alone [8]. In
contrast, IL-6 release from ASM is increased by β2-agonists
in both asthmatic [1] and nonasthmatic cells [1, 29], and our
ﬁndings in the current study conﬁrm this.
Thestudyofcellsincultureisassociatedwithlimitations,
and this is where we ﬁnd the bronchial ring preparation a
useful model. It enables us to observe, in an “intact” airway,
changes in ECM proteins [1, 17] and cytokine deposition
[15, 30] in response to proﬁbrotic stimuli such as TGFβ
and, in addition, to investigate the eﬀects of intervention
with relevant therapeutic agents such as LABAs and cor-
ticosteroids. Here we conﬁrmed our previous ﬁndings [1]
that neither LABAs nor corticosteroids alone decreased ﬁ-
bronectin deposition in response to TGFβ and extended
them to include the combination of the two drug classes
which were without eﬀect. In contrast, we have previously
reported that the phosphodiesterase inhibitor roﬂumilast
abolished TGFβ-induced ﬁbronectin deposition [1].
In summary, in our cell and tissue models of ECM pro-
tein deposition, we investigated whether the combination of
a LABA and a corticosteroid would be more eﬀective in in-
hibiting or reversing TGFβ-induced ﬁbronectin release. This
was not the case either in cells derived from asthmatic or
nonasthmaticvolunteers,orinintactbronchialrings.Airway
remodeling is detrimental in the pathophysiology of asthma,
and ECM protein deposition is a major component of
said remodeling; therefore, these results highlight the need
for further development of agents to reverse or prevent
parameters of airway remodeling.
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